Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-261,097
Closed -$1.18M 13159
2025
Q4
$1.18M Buy
261,097
+144,033
+123% +$738K ﹤0.01% 7028
2025
Q3
$631K Buy
+117,064
New +$633K ﹤0.01% 8571
2024
Q4
Sell
-1,011,537
Closed -$2.92M 14642
2024
Q3
$2.97M Buy
1,011,537
+751,007
+288% +$2.47M ﹤0.01% 4796
2024
Q2
$886K Sell
260,530
-719,974
-73% -$2.35M ﹤0.01% 6833
2024
Q1
$2.97M Buy
980,504
+78,006
+9% +$274K ﹤0.01% 4809
2023
Q4
$3.8M Sell
902,498
-2,171,495
-71% -$11.8M ﹤0.01% 4224
2023
Q3
$21M Buy
3,073,993
+720,193
+31% +$6.36M ﹤0.01% 1809
2023
Q2
$24.5M Sell
2,353,800
-581,503
-20% -$5.2M 0.01% 1683
2023
Q1
$20.5M Buy
2,935,303
+954,433
+48% +$8.32M ﹤0.01% 1892
2022
Q4
$11.9M Buy
1,980,870
+1,909,554
+2,678% +$14.1M ﹤0.01% 2572
2022
Q3
$562K Sell
71,316
-53,014
-43% -$618K ﹤0.01% 8202
2022
Q2
$1.69M Sell
124,330
-172,270
-58% -$2.85M ﹤0.01% 5887
2022
Q1
$5.82M Buy
296,600
+279,368
+1,621% +$5.58M ﹤0.01% 3885
2021
Q4
$591K Sell
17,232
-42,899
-71% -$1.73M ﹤0.01% 9272
2021
Q3
$3.29M Buy
60,131
+51,585
+604% +$3.11M ﹤0.01% 5163
2021
Q2
$628K Buy
8,546
+5,624
+192% +$562K ﹤0.01% 9505
2021
Q1
$267K Sell
2,922
-14,332
-83% -$1.39M ﹤0.01% 11107
2020
Q4
$1.4M Buy
+17,254
New +$1.32M ﹤0.01% 6081

Ken Griffin's CVAC Position: Q1 2026 in Review

Ken Griffin sold out of CureVac (CVAC) in Q1 2026, closing a stake of 261,097 shares — an estimated $1.18M sold.

Ken Griffin first reported a position in CVAC in Q4 2020 and held it in 18 quarters. The position peaked at $24.5M in Q2 2023. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.

  • Ken Griffin reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 261,097 CureVac shares in Q1 2026, an estimated $1.18M.
  • Ken Griffin first reported a position in CureVac in Q4 2020 and held it in 18 quarters.
  • Ken Griffin's CureVac position peaked at $24.5M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.